Cyclopropyl methanone derivatives,their preparation and their therapeutic use

Interest in the development of novel histamine H₃ antagonists, especially for the treatment of obesity and CNS disorders, remains strong, as evidenced by recent patent activity from a large number of pharmaceutical companies. The present application from Sanofi-Aventis discloses a series of cyclopropyl methanone derivatives that display high receptor binding affinity and selectivity for the H₃ receptor together with an ability to reduce food intake in rat.